DNA damage response companies research the cellular pathways that detect, repair and respond to damaged DNA. These mechanisms are important in cancer biology, genomic stability and the development of targeted therapeutics.
This category includes companies working on:
Browse 17 UK DNA damage response companies below.
Small molecule inhibitors targeting APOBEC enzymes in cancer
Apobec Discovery is a preclinical-stage biotechnology company developing first-in-class small molecule inhibitors of APOBEC3A and APOBEC3B, cytidine deaminase enzymes that drive tumour mutagenesis, evolution, and resistance to treatment. By blocking APOBEC activity, the company aims to limit the mutational capacity of…
Small molecule MMR inhibitors to enhance tumour immunogenicity
NeoPhore is a UK immuno-oncology company developing first-in-class small molecule inhibitors of the DNA mismatch repair pathway. By transiently blocking MMR, the company's compounds render tumours MMR-deficient and immunogenic, generating neoantigens that stimulate immune responses against cancer. The approach aims to…
Clinical-stage biopharma improving nucleoside analogue chemotherapy efficacy
NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry. Its approach transforms established nucleoside analogue chemotherapy agents into modified forms that bypass key tumour resistance mechanisms, delivering higher…
Sequencing kits for genome-wide off-target analysis of gene editing
Broken String Biosciences is a genomics company that develops tools for measuring the safety of genome editing. Its platform uses next-generation sequencing to map DNA breaks and editing intermediates across the genome, allowing developers to detect and quantify on-target and off-target edits made by nucleases and…
Precision oncology biotech targeting synthetic lethality in cancer
Tessellate Bio is a precision oncology company developing small molecule drugs that exploit synthetic lethality, the principle that certain genetic vulnerabilities in cancer cells can be targeted to selectively kill tumour cells. The company's lead programme targets the FANCM complex in cancers relying on Alternative…
Sperm DNA fragmentation diagnostics for male fertility assessment
Examen is a Belfast-based diagnostics company specialising in male reproductive health. Its proprietary assay-based technology measures single-strand and double-strand sperm DNA breaks to provide a clinically actionable assessment of male fertility beyond conventional semen analysis parameters. Tests are…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA…
Precision oncology biotech targeting novel DNA damage response pathways
Nodus Oncology is a preclinical-stage biotechnology company developing small molecule inhibitors against novel DNA damage response targets for molecularly defined cancer patient populations. The company's pipeline is focused on synthetic lethality and collateral vulnerabilities in tumours with specific DNA repair…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…
Small molecule inhibitors targeting somatic expansion in neurodegeneration
LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat expansion disorders. The company targets MutSβ, a protein complex whose aberrant activity drives somatic expansion and progressive…
First-in-class small molecule therapeutics targeting DNA uracilation in cancer
CV6 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule drugs for cancer and inflammatory diseases. Its lead asset CV6-168 is a specific inhibitor of the enzyme dUTPase, inducing uracil misincorporation into cancer cell DNA, triggering DNA damage and immune activation.…
Academic cancer research institute and drug discoverer
The Institute of Cancer Research (ICR) is an independent research institute and member institution of the University of London, specialising in cancer biology, drug discovery, genetics, and precision radiotherapy. Working closely with the Royal Marsden NHS Foundation Trust, the ICR has discovered cancer medicines…
Targeted small-molecule drugs for brain and metastatic cancers
Sentinel Oncology is a biotechnology company developing targeted small-molecule drugs for difficult-to-treat cancers. Its medicinal chemistry programmes investigate DNA damage responses and cell division. Some candidates are designed to cross the blood-brain barrier, targeting primary brain tumours and cancers that…
Cancer Research UK's translational and commercialisation arm
Cancer Research Horizons is the translational subsidiary of Cancer Research UK, operating at the interface between academic research and industry. The organisation combines in-house drug discovery expertise across six UK sites with technology transfer, licensing, and early-stage venture investment activities. It…
Human iPSC-based safety and genotoxicity testing for gene therapy vectors
TestAVec is a provider of in vitro safety testing services for gene therapy and viral vector products, serving academic researchers and industry developers. The company's human stem cell based platform assesses vector-induced genotoxicity, evaluates patients' DNA repair capacity ahead of radiation or chemotherapy, and…
Computational cell models for novel drug target discovery
Oppilotech is a UK biotechnology company that uses systems biology and machine learning to build high-resolution computational models of cells and bacteria. Its proprietary platform simulates biochemical pathways to identify viable drug targets and generate first-in-class discovery programmes. The company's primary…
Oncology biotech creation studio developing and spinning out cancer therapies
Cumulus Oncology is a company creation studio specialising in oncology drug discovery and development. The company identifies and sources novel cancer therapeutic assets from academic and commercial organisations, funds them, and incorporates them into newly created spin-out biotechs. Cumulus provides scientific…